VivoSeq
Cardiovascular

Atherosclerotic Cardiovascular Disease

2

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Atherosclerotic Cardiovascular Disease is an early-stage landscape with 2 programs across 4 companies. The most active players are Cyclarity Therapeutics, Inc., Amgen, Eli Lilly. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cyclarity Therapeutics, Inc.

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Sanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

UDP-003

Cyclarity Therapeutics, Inc.

Phase 2
No programs
Phase 31

Maridebart Cafraglutide

Amgen

Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Peptide150%

Modality classified for 67% of 3 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Completed1 · 33%

Clinical Trials

Trial Activity

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Recruiting·Amgen logoAmgen·Phase 3·NCT07037433·12,800 enrolled
Reduction in Low-Density Lipoprotein Cholesterol With Alirocumab 150 mg as Compared With Inclisiran: Comparative Evaluation Via Target-Trial Emulation and G-Computation
Completed·Sanofi logoSanofi·N/A·NCT07615166·996 enrolled
A Double Blind, Placebo-controlled Study in Healthy Participants to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of UDP-003 and Followed by an Open-label Multiple-dose Patient Cohort
Recruiting·CCyclarity Therapeutics, Inc.·Phase 1·NCT06813339·84 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)